Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents
UMass Chan Affiliations
Department of PediatricsDocument Type
Journal ArticlePublication Date
2000-09-01Keywords
Angioplasty, Balloon, CoronaryAntibodies, Monoclonal
Coronary Disease
Fibrinolytic Agents
Heart Catheterization
Humans
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Stents
Ticlopidine
Hematology
Oncology
Pediatrics
Metadata
Show full item recordAbstract
Pharmacologic advances in the use of antithrombotic agents have paralleled the technologic innovations used in patients undergoing coronary interventions. The recognition of the central role of platelets in the development of complications related to coronary interventions led to the investigation and subsequent routine use of several antiplatelet agents as adjuvants to coronary intervention. Thus, the oral agents aspirin and either ticlopidine or clopidogrel are routinely administered after coronary stenting. Intravenous glycoprotein (GP) IIb/IIIa antagonists have been extensively studied and reduce adverse cardiac events in patients undergoing coronary interventions, especially those receiving intracoronary stents. Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems.Source
Curr Cardiol Rep. 2000 Sep;2(5):386-94. DOI: 10.1007/s11886-000-0051-0DOI
10.1007/s11886-000-0051-0Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43346PubMed ID
10980905Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/s11886-000-0051-0